Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

Similar articles for PubMed (Select 18486273)

1.

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP.

Lung Cancer. 2009 Jan;63(1):94-7. doi: 10.1016/j.lungcan.2008.04.001. Epub 2008 May 16.

PMID:
18486273
2.

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J.

Cancer. 2007 Jan 1;109(1):93-9.

3.

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A.

Cancer. 2008 Apr 1;112(7):1555-61. doi: 10.1002/cncr.23337.

4.

Phase II study of vinorelbine in patients with malignant pleural mesothelioma.

Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM.

J Clin Oncol. 2000 Dec 1;18(23):3912-7.

PMID:
11099320
5.

Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.

Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.

In Vivo. 2006 Nov-Dec;20(6A):715-8.

6.

Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.

Fennell DA, C Steele JP, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM.

Lung Cancer. 2005 Feb;47(2):277-81.

PMID:
15639727
7.

Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.

Steer J, Bough G, Razak AR, Meachery GJ, Hughes A.

Clin Oncol (R Coll Radiol). 2010 Apr;22(3):231-5. doi: 10.1016/j.clon.2010.01.009.

PMID:
20346340
8.

Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.

Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, Ardizzoni A, Fumagalli L, Valsuani G, Botta M.

Lung Cancer. 2001 Feb-Mar;31(2-3):303-10.

PMID:
11165411
9.

Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.

van den Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF, Hoogsteden HC, van Klaveren RJ.

J Thorac Oncol. 2006 Jan;1(1):25-30.

PMID:
17409823
10.

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.

Lung Cancer. 2014 Jun;84(3):265-70. doi: 10.1016/j.lungcan.2013.11.011. Epub 2013 Nov 20.

PMID:
24321581
11.

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.

Astoul P, Picat-Joossen D, Viallat JR, Boutin C.

Cancer. 1998 Nov 15;83(10):2099-104.

PMID:
9827714
12.

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK; Pemetrexed expanded access program investigators.

J Thorac Oncol. 2006 Jul;1(6):506-12. Erratum in: J Thorac Oncol. 2006 Sep;1(7):621.

PMID:
17409909
13.

Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.

Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.

J Thorac Oncol. 2008 Jul;3(7):764-71. doi: 10.1097/JTO.0b013e31817c73ec.

PMID:
18594323
14.

A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.

Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E.

Cancer Chemother Pharmacol. 2012 Nov;70(5):743-54. doi: 10.1007/s00280-012-1965-0. Epub 2012 Sep 8.

PMID:
22960937
15.

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.

Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C.

J Clin Oncol. 2008 Apr 1;26(10):1698-704. doi: 10.1200/JCO.2006.09.9887.

16.

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.

Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C.

J Clin Oncol. 2010 May 20;28(15):2604-11. doi: 10.1200/JCO.2009.27.3649. Epub 2010 Apr 20.

17.

Phase II study of vinflunine in malignant pleural mesothelioma.

Talbot DC, Margery J, Dabouis G, Dark G, Taylor H, Boussemart H, Cadic V, Pinel MC, Rivière A, Ollivier L, Ruffié P.

J Clin Oncol. 2007 Oct 20;25(30):4751-6.

18.

Phase II trial of ZD0473 as second-line therapy in mesothelioma.

Giaccone G, O'Brien ME, Byrne MJ, Bard M, Kaukel E, Smit B.

Eur J Cancer. 2002 Dec;38 Suppl 8:S19-24.

PMID:
12647701
19.

Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.

Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M.

Jpn J Clin Oncol. 2008 May;38(5):339-46. doi: 10.1093/jjco/hyn024. Epub 2008 Apr 22.

20.

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.

Sørensen JB, Frank H, Palshof T.

Br J Cancer. 2008 Jul 8;99(1):44-50. doi: 10.1038/sj.bjc.6604421. Epub 2008 Jun 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk